|
|
|
|
|
|
Sponsors and Collaborators: |
Manhattan Eye, Ear & Throat Hospital Alcon Research |
Information provided by: | Manhattan Eye, Ear & Throat Hospital |
ClinicalTrials.gov Identifier: | NCT00211354 |
Retinal Vein Occlusion is a blockage of the blood vessels that drain out of the retina. Complications of retinal vein occlusion which threaten vision include neovascularization(growth of new blood vessels)and macular edema ( accumulation of fluid "leaking" from abnormal blood vessels). Currently, the treatment of retinal vein occlusion is laser photocoagulation. This treatment has found to have limited use in this type of condition.Anecortave Acetate is being considered as an attempt to control the growth of the abnormal blood vessels.
Condition | Intervention | Phase |
Retinal Vein Occlusion |
Drug: Anecortave Acetate |
Phase II |
ChemIDplus related topics: | Anecortave acetate |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
United States, New York | |||||
Manhattan Eye, Ear & Throat Hospital | |||||
New York, New York, United States, 10021 |
Manhattan Eye, Ear & Throat Hospital |
Alcon Research |
Principal Investigator: | Lawrence A. Yannuzzi, MD | Manhattan Eye, Ear & Throat Hospital |
Study ID Numbers: | AA in RVO |
First Received: | September 13, 2005 |
Last Updated: | June 20, 2007 |
ClinicalTrials.gov Identifier: | NCT00211354 |
Health Authority: | United States: Food and Drug Administration |
|
|
|